Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data presented at AAIC Read more
FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment Read more
Eisai to grant 625 mn yen to GHIT Fund for developing medicines for neglected tropical diseases, malaria Read more